Pulmonology · Environmental Medicine

High Altitude Sickness

USMLE2PANCE
7

Bets

The facts most likely to be tested

1

Acute Mountain Sickness (AMS) presents with headache accompanied by fatigue, gastrointestinal distress, or dizziness following rapid ascent to altitudes typically above 2,500 meters.

Confidence:
2

Acetazolamide is the first-line pharmacologic agent for both the prevention and treatment of AMS by inducing a metabolic acidosis that stimulates ventilation.

Confidence:
3

High-Altitude Pulmonary Edema (HAPE) is a life-threatening condition characterized by non-cardiogenic pulmonary edema caused by exaggerated pulmonary hypertension in response to hypoxia.

Confidence:
4

Descent is the definitive and most effective treatment for all forms of severe high-altitude illness, including HAPE and High-Altitude Cerebral Edema (HACE).

Confidence:
5

High-Altitude Cerebral Edema (HACE) is the most severe form of altitude illness, manifesting as ataxia, altered mental status, and papilledema due to increased intracranial pressure.

Confidence:
6

Nifedipine is the preferred treatment for HAPE when immediate descent is not possible, as it reduces pulmonary artery pressure.

Confidence:
7

Dexamethasone is the mandatory adjunctive treatment for HACE to reduce vasogenic edema while facilitating immediate descent.

Confidence:

Vignette unlocked

A 32-year-old hiker is brought to the base camp after ascending to 4,000 meters over the last 24 hours. He complains of a severe, throbbing headache, nausea, and persistent vomiting. On physical examination, he is noted to have truncal ataxia and confusion. His oxygen saturation is 78% on room air, and lung auscultation reveals clear breath sounds without crackles.

What is the most appropriate next step in management?

+Reveal answer

Immediate descent and administration of dexamethasone

The patient's presentation of ataxia and altered mental status is diagnostic of HACE, which requires immediate descent and high-dose dexamethasone to reduce cerebral edema.

Mo

Depth

Full handout

High yield triage

Etiology / Epidemiology

Occurs due to rapid ascent to altitudes >2,500m. Hypobaric hypoxia is the primary trigger.

Clinical Manifestations

AMS presents as hangover-like headache. HACE shows ataxia; HAPE shows crackles.

Diagnosis

Clinical diagnosis. Lake Louise Score for AMS. Pulse oximetry shows low SpO2.

Treatment

Acetazolamide is first-line for prevention/treatment. Do not use in sulfa allergy.

Prognosis

Descent is curative. Pulmonary edema is the leading cause of death.

Full handout

Epidemiology & Etiology

Risk is determined by rate of ascent and final altitude rather than physical fitness. Individuals with a history of altitude illness are at highest risk for recurrence. Rapid transit to altitudes exceeding 2,500 meters triggers the physiological maladaptation.

Pertinent Anatomy

The primary anatomical impact involves the pulmonary vasculature and cerebral microvasculature. Hypoxia-induced pulmonary vasoconstriction leads to increased pulmonary artery pressure. Cerebral capillary leakage results from impaired blood-brain barrier integrity.

Pathophysiology

Low partial pressure of oxygen triggers hyperventilation, causing respiratory alkalosis. Failure to acclimatize leads to fluid retention and cerebral edema (HACE) or pulmonary edema (HAPE). HAPE is specifically driven by uneven hypoxic pulmonary vasoconstriction causing capillary stress failure.

Clinical Manifestations

AMS manifests as headache, nausea, and fatigue. HACE is defined by ataxia and altered mental status, representing a neurological emergency. HAPE presents with dyspnea at rest, tachycardia, and pink frothy sputum. Altered mental status or ataxia mandates immediate descent.

Diagnosis

Diagnosis is strictly clinical. The Lake Louise Score is used for AMS assessment. Pulse oximetry is useful but not diagnostic; values are typically lower than predicted for altitude. Chest X-ray in HAPE shows patchy alveolar infiltrates.

Treatment

Acetazolamide is the gold standard for prophylaxis and treatment. For HACE/HAPE, dexamethasone and nifedipine are critical adjuncts. Avoid sedatives as they suppress respiratory drive. Supplemental oxygen and immediate descent are the definitive treatments.

Prognosis

Most cases resolve within 24-48 hours with rest or descent. HAPE and HACE carry high mortality if untreated, with cerebral herniation being the primary cause of death in HACE. Patients must be monitored for hypoxemia until symptoms resolve.

Differential Diagnosis

Dehydration: absence of neurological deficits

Carbon monoxide poisoning: history of enclosed space exposure

Pneumonia: presence of fever and purulent sputum

Congestive heart failure: history of cardiac disease

Migraine: lack of altitude exposure history